Sensorium signs $30 million deal to advance drug discovery engine



Sensorium Therapeutics, announced the closing of a $30 million round of funding to advance its seed asset, SENS-01, and Biodynamic Discovery Platform (BDP).

The platform is a drug discovery engine that rapidly identifies, synthesizes and improves molecules targeted as therapeutics. The round was led by Santé Ventures, a healthcare and life sciences investment firm with approximately $1 billion in capital under management, with participation from Route 66 Ventures, CU Healthcare Innovation Fund,, Palo Santo, Iter Investments, Ocama Partners, and re.Mind Capital.

Dick Simon, CEO and Co-Founder of Sensorium, said: “To address this devastating mental health crisis, we urgently need to expand the universe of safe and effective treatments by leveraging knowledge about what has worked. in human populations for centuries.

Sensorium reaches an agreement

“The complexity of the challenge requires clinical, scientific and technical expertise. Sensorium’s multidisciplinary team embodies a wealth of industry and academic experience with a passion and track record of impact.

US-based Sensorium says that with scientific co-founders expert in psychiatry, chemistry and neuroscience at leading institutions, it seeks to overcome the historical challenges of central nervous system drug development by harnessing the vast space chemistry of psychoactive molecules to develop new drugs. that respond to the global crisis.

Starting with evidence of efficacy and safety based on long-term intensive human use, the company explained that BDP feeds data outputs from its library of natural products and high-throughput characterization into algorithms for proprietary machine learning.

Advancing the Drug Discovery Platform

He says that by prioritizing mechanisms with established efficacy in the human brain, the platform enables Sensorium to deliver modern drugs faster and with improved efficacy and tolerability, fewer side effects and potential reduced dependency.

The company’s initial asset, SENS-01, shows promise in providing rapid therapeutic effect for the treatment of anxiety. Sensorium is developing SENS-01 as a fast-acting, well-tolerated therapeutic for patients with anxiety and depression and plans to begin IND-enabled studies in 2023 and enter the clinic in early 2024.

Kevin Lalande, Founding CEO of Santé Ventures, said, “Sensorium’s transformational technology and experienced research team have the potential to revolutionize neuropsychiatric therapy by developing several new classes of novel therapies.

Support from the Sensorium team

“We are thrilled to support the Sensorium team in their mission to forge these new treatment pathways and provide new medicines to the many patients facing urgent mental health needs.”

“By better understanding the impact of new psychoactive molecules on the brain, we unlock critical information to deliver transformative medicines to patients for whom existing treatments fall short and who desperately await innovation,” said Jerry Rosenbaum, co- founder of Sensorium.

Co-founder Jacob Hooker said the company’s predictive knowledge network of psychoactive molecules identifies structure-activity relationships. He added: “These act as a springboard for developing new drugs with optimized therapeutic benefit. Nature has provided the model, and we know we can do better.

Growth of the Sensorium team

Stephen Haggarty concluded: “Humans have been consuming psychoactive molecules for centuries, but how they work remains a challenge to understand.

“Our approach combines deep knowledge of the chemical space with a platform that interrogates drug function on neuronal plasticity and other indicators to generate potential drug candidates.”

The funding will support the advancement of Sensorium’s platform and initial program and also help ensure the growth of the company’s multidisciplinary team of experts passionate about improving mental health.

Source link


Comments are closed.